U.S. Food and Drug Administration (USFDA) completed an inspection at the company's manufacturing facility in Roha, Raigad with the classification as ‘no action indicated', the company announced through an exchange filing. Based on the inspection the facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice.
The inspection by the USFDA was conducted between March 20 and March 24, 2023. The inspection has concluded and a copy of the narrative portion of the Establishment Inspection Report has been issued.
The Active Pharmaceutical Ingredients (API’s) product manufactured at the above facility continues to be marketed in the USA.
USFDA conducts audit at Aurangabad facility
USFDA in February had conducted an audit at FDC's Aurangabad manufacturing facility and closed it with no observations.
FDC Shares
The shares of FDC Limited on Thursday at 2:27 pm IST were at Rs 307.15, down by 0.60 per cent.
(To receive our E-paper on WhatsApp daily, please click here. To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)
